LGM Pharma

Anakinra

CAS No: 143090-92-0

Anakinra

LGM Pharma is a Anakinra 143090-92-0 active pharmaceutical ingredient supplier distributor, based in the USA.

Questions? Call our customer API support number 1-(800)-881-8210.

LGM Pharma offers this active ingredient but not the finished dosage forms.

Inquire about Anakinra

Product Details:

CAS No: 143090-92-0
Synonyms: ICIL-1RA, IL-1ra, IL-1RN, IL1 inhibitor, Interleukin-1 receptor antagonist protein precursor, IRAP
ATC code: L04AC03
Molecular Weight: 17
257.6 g/mol
Chemical Formula: C759H1186N208O232S10
DrugBank: DB00026
Assay/Purity: Typically NLT 98%
IUPAC Name: Recombinant human Interleukin-1 receptor antagonist protein; syn. N2-l-methionyl-interleukin 1 receptor antagonist (human isoform x reduced)

Additional Details: [+]

Pharmacodynamics:

Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.

Mode of Action:

Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.

Metabolism:

renal

General Reference:
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI): Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008 Mar;67(3):281-2.
    Pubmed

Anakinra News:

  • The FDA has approved Anakinra CAS# 143090-92-0 marketed as Kineret® for the treatment of children and adults with neonatal-onset multisystem inflammatory disease (NOMID). Kineret® is the first and only FDA-approved therapy for NOMID, the most severe form of cryopyrin associated periodic syndromes (CAPS).
  • 5 years of treatment with NOMID patients demonstrated that, in addition to controlling the daily symptoms of the disease, hearing and vision remain stable and do not progress on treatment.
  • Certain cases of NOMID cause severe symptoms, like headaches, seizures and vomiting which result from chronic meningitis.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.